Syncom Formulations (India) Limited (NSE:SYNCOMF)

India · Delayed Price · Currency is INR

19.97

-0.04 (-0.20%)

Sep 24, 2026, 12:55 PM IST

Market Cap	18.83B +14.1%
Revenue (ttm)	4.98B +0.6%
Net Income	855.30M +48.6%
EPS	0.90 +17.2%
Shares Out	n/a
PE Ratio	22.01
Forward PE	n/a
Dividend	0.10 (0.50%)
Ex-Dividend Date	Sep 23, 2026

Volume	8,423,535
Open	20.01
Previous Close	20.01
Day's Range	19.82 - 20.75
52-Week Range	10.21 - 22.59
Beta	0.80
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About NSE:SYNCOMF

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, an... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1988

Employees 902

Stock Exchange National Stock Exchange of India

Ticker Symbol SYNCOMF

Full Company Profile

Financial Performance

In fiscal year 2026, NSE:SYNCOMF's revenue was 4.89 billion, an increase of 5.20% compared to the previous year's 4.65 billion. Earnings were 764.38 million, an increase of 54.62%.

Financial Statements